Armata Pharmaceuticals (ARMP) Income from Continuing Operations (2013 - 2026)
Armata Pharmaceuticals (ARMP) posted Income from Continuing Operations of 67182000.0 for Q1 2026, down 260.09% sequentially from 18657000.0 in Q4 2025, and down 469.68% YoY from 18173165.57 in Q1 2025.
Armata Pharmaceuticals (ARMP) Income from Continuing Operations (2013 - 2026) Analysis & Trends
Armata Pharmaceuticals has reported Income from Continuing Operations for 14 years, with the latest figure at 67182000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 469.68% year-over-year to 67182000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 167077000.0 (up 10.43% YoY) and the FY2025 annual result came in at 134410000.0, down 6.12% from the prior year.
- Income from Continuing Operations eased to 67182000.0 in Q1 2026 per ARMP's latest filing, from 18657000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 10011000.0 in Q3 2022 and troughed at 81329000.0 in Q2 2024.
- A 5-year average of 27231085.41 and a median of 13531000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations slumped 561.76% in 2024, then jumped 84.68% in 2025.
- Over 5 years, Income from Continuing Operations stood at 10315452.0 in 2022, then retreated by 6.26% to 10961000.0 in 2023, then plunged by 60.05% to 17543000.0 in 2024, then declined by 6.35% to 18657000.0 in 2025, then sank by 260.09% to 67182000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 67182000.0, 18657000.0, and 68778000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Armata Pharmaceuticals | 182.82 Mn | 158.82 Mn | - | -16.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.38 Mn |
| Mar 31, 2026 | -67.18 Mn |
| Dec 31, 2025 | -18.66 Mn |
| Sep 30, 2025 | -68.78 Mn |
| Jun 30, 2025 | -12.46 Mn |
| Mar 31, 2025 | -11.79 Mn |
| Dec 31, 2024 | -17.54 Mn |
| Sep 30, 2024 | -75.87 Mn |
| Jun 30, 2024 | -81.33 Mn |
| Mar 31, 2024 | -13.53 Mn |
| Dec 31, 2023 | -10.96 Mn |
| Sep 30, 2023 | -11.47 Mn |
| Jun 30, 2023 | -14.99 Mn |
| Mar 31, 2023 | -16.53 Mn |
| Dec 31, 2022 | -10.32 Mn |
| Sep 30, 2022 | -10.01 Mn |
| Jun 30, 2022 | -10.14 Mn |
| Mar 31, 2022 | -11.37 Mn |
| Dec 31, 2021 | -8.18 Mn |
| Sep 30, 2021 | -6.75 Mn |